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Abstract: Thyroid dysfunction has a great impact on lipids as well as a number of other cardiovascular risk factors.  
Hypothyroidism is relatively common and is associated with an unfavorable effect on lipids. Substitution therapy is bene-
ficial for patients with overt hypothyroidism, improving lipid profile. However, whether subclinical hypothyroidism 
should be treated or not is a matter of debate. On the other hand, hyperthyroidism can be associated with acquired hypo-
cholesterolemia or unexplained improvement of lipid profile. Overall, thyroid dysfunction should be taken into account 
when evaluating and treating dyslipidemic patients. 
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1. INTRODUCTION 
  Thyroid function regulates a wide array of metabolic 
parameters. Thyroid function significantly affects lipoprotein 
metabolism as well as some cardiovascular disease (CVD) 
risk factors, thus influencing overall CDV risk [1-3]. Indeed, 
even within the normal range of thyroid-stimulating hor-
mone (TSH) values, a linear increase in total cholesterol 
(TC), low-density lipoprotein cholesterol (LDL-C) and 
triglycerides (TGs) and a linear decrease in high-density 
lipoprotein cholesterol (HDL-C) levels has been observed 
with increasing TSH [4]. 
2. MECHANISMS (FIG. 1) 
  Thyroid hormones induce the 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, which is the first step 
in cholesterol biosynthesis. Moreover, triiodothyronine (T3) 
upregulates LDL receptors by controlling the LDL receptor 
gene activation. This T3-mediated gene activation is done by 
the direct binding of T3 to specific thyroid hormone respon-
sive elements (TREs) [5]. Furthermore, T3 controls the sterol 
regulatory element-binding protein-2 (SREBP-2), which in 
turn regulates LDL receptor’s gene expression [6]. T3  
has also been associated with protecting LDL from oxidation 
[7]. 
  Thyroid hormones can influence HDL metabolism by 
increasing cholesteryl ester transfer protein (CETP) activity, 
which exchanges cholesteryl esters from HDL2 to the very 
low density lipoproteins (VLDL) and TGs to the opposite 
direction [8]. In addition, thyroid hormones stimulate the 
lipoprotein lipase (LPL), which catabolizes the TG-rich lipo-
proteins, and the hepatic lipase (HL), which hydrolyzes 
HDL2 to HDL3 and contributes to the conversion of interme-
diate-density lipoproteins (IDL) to LDL and in turn LDL to  
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small dense LDL (sdLDL) [9, 10]. Another effect of T3 is the 
up-regulation of apolipoprotein AV (ApoAV), which plays a 
major role in TG regulation [11]. Indeed, increased levels of 
ApoAV have been associated with decreased levels of TGs 
[12]. Proposed mechanisms for this effect include the de-
crease of hepatic VLDL-TG production and the increase of 
plasma LPL levels and activity, resulting in increase of lipo-
protein remnant generation due to enhanced LPL-mediated 
lipolysis of VLDL-TG [12]. Moreover, a greater clearance of 
lipoprotein core remnants, caused by increased hepatic up-
take due to an enhanced affinity for the LDL receptor, has 
also been ascribed to ApoAV [12]. 
  Beyond their effect on lipid profile thyroid hormones can 
equally affect a number of other metabolic parameters re-
lated to CVD risk. Indeed, thyroid function can influence 
adipocyte metabolism and the production of adipokines [13-
15]. Hyperthyroidism has been associated with increased 
levels of adiponectin, whereas hypothyroidism is not associ-
ated with significant changes in adiponectin [13, 15]. Insulin 
resistance is also correlated with thyroid function [16-19]. 
TSH is positively associated with fasting and postprandial 
insulin concentration and negatively with insulin sensitivity 
[17]. Moreover, low normal FT4 levels are significantly as-
sociated with increased insulin resistance [19]. Oxidative 
stress is also affected by thyroid function with studies how-
ever showing controversial outcomes [7, 20]. Furthermore, 
endothelial [17] and cardiac function as well as atherosclero-
sis [21] have been positively associated with thyroid hor-
mone levels. A positive association between TSH and body 
mass index (BMI) or waist circumference has also been de-
scribed [22, 23]. A large population trial using data from the 
fourth and fifth Tromso study showed that this association 
between TSH and BMI was only significant in non smokers 
[24]. 
  The effects of thyroid dysfunction on lipid parameters 
and CVD risk factors as well as the influence of substitution 
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3. HYPOTHYROIDISM 
  Hypothyroidism is a common metabolic disorder in the 
general population. Indeed, data from the third National 
Health and Nutrition Examination Survey (NHANES III) 
showed a 4.6% prevalence of hypothyroidism in the general 
population, while 9.5% of the Colorado prevalence study 
participants had elevated levels of TSH [3]. Thyroid failure 
is more common in women and its prevalence rises with age. 
Hypothyroid patients have increased levels of TC and LDL-
C [3]. Indeed, hypothyroidism is a common cause of secon-
dary dyslipidemia [25, 26]. 
i. Overt Hypothyroidism 
a. Lipid Profile 
  Although decreased thyroid function is accompanied by 
reduced activity of HMG-CoA reductase, TC and LDL-C 
levels are increased in patients with overt hypothyroidism 
[27-31]. This is due to the decreased LDL-receptors’ activ-
ity, resulting in decreased catabolism of LDL and IDL [32-
34]. Moreover, a decrease in LPL activity is found in overt 
hypothyroidism, decreasing the clearance of TG-rich lipo-
proteins [35]. Therefore, overt hypothyroid patients may also 
present with elevated TG levels associated with increased 
levels of VLDL and occasionally fasting chylomicronemia 
[29-31, 34]. The VLDL and IDL particles in hypothyroidism 
are rich in cholesterol and apolipoprotein E, thus resembling 
-VLDL particles of type III hyperlipoproteinemia. There-
fore, the full-blown clinical syndrome of the type III hyper-
lipoproteinemia may develop in patients homozygous for the 
apolipoprotein E2 allele if they become hypothyroid. 
  Hypothyroid patients may also exhibit elevated levels of 
HDL-C [27] mainly due to increased concentration of HDL2 
particles. Indeed, due to a reduction of HL activity a de-
crease in HDL2 catabolism is observed. [36]. Moreover, de-
creased activity of the CETP results in reduced transfer of 
cholesteryl esters from HDL to VLDL, thus increasing HDL-
C levels [37]. Hypothyroid patients have increased lipopro-
tein (a) [Lp(a)] levels [38, 39], which are associated with 
increased CVD risk [39, 40]. 
  Beyond the levels of LDL-C, the qualitative composition 
of LDL-C plays an important role in CVD development. 
Indeed, increased sdLDL concentration increases the risk for 
CVD [41]. Trials evaluating the effects of overt hypothyroid-
ism on LDL subfractions have shown conflicting results. A 
study in newly-diagnosed hypothyroid patients (n=60) 
showed that hypothyroidism was associated with higher 
prevalence of sdLDL [28]. On the other hand, there have 
been studies showing no significant differences between 
overt hypothyroid patients and healthy controls regarding 
sdLDL levels [42, 43]. Another study evaluated the effects 
of short-term overt hypothyroidism on LDL subfractions 
[27]. Thyroidectomized patients (n=28) were withdrawn 
from substitution therapy for 2-3 weeks in preparation for 
radioactive iodine ablation. Patients exhibited an increase in 
LDL-C that was found to be primarily due to increases in the 
large LDL particles, while sdLDL did not significantly 
change [27]. 
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b. CVD Risk 
  The above abnormalities of lipid metabolism associated 
with overt hypothyroidism predispose to the development of 
atherosclerotic coronary artery disease (CAD) [44, 45]. 
Moreover, hypothyroidism can adversely affect other CVD 
risk factors, further contributing to increasing CAD risk. 
Decreased thyroid function not only increases the number of 
LDL particles, but also promotes LDL oxidability [46]. Fur-
thermore, hypothyroidism increases plasma homocysteine 
levels [47-50], which can be attributed to the hypothyroid-
ism-induced decline of kidney function [51] as well as im-
paired methylenetetrahydrofolate reductase activity [52]. In 
addition, thyroid failure is strongly associated with arterial 
hypertension (especially diastolic) [53-55] via  sympathetic 
and adrenal activation [53], and increased vascular stiffness 
[54, 56, 57]. Subjects with overt hypothyroidism also exhibit 
impaired endothelial function [58], increased uric acid [28] 
and phosphate levels [29], all of which are associated with 
increased CVD risk [59, 60]. 
  In addition, an increase in carotid intima media thickness 
(CIMT) has been observed in hypothyroid patients [61]. Hy-
pothyroidism is also accompanied by increased prevalence 
of metabolic syndrome [62] and waist-to-hip ratio [63]. Insu-
lin resistance is increased in thyroid failure [64], while a 
decrease in GLUT4 glucose transporters (leading to a reduc-
tion of glucose uptake and promoting insulin resistance [65]) 
is observed [64]. Moreover, there are indications of in-
creased high-sensitivity C-reactive protein (hsCRP) levels in 
hypothyroidism [28, 49] although there are studies which do 
not support this notion [31, 50]. 
c. Substitution Therapy 
  Administration of substitution therapy with L-thyroxine 
significantly improves lipid metabolism abnormalities. A 
period of 4-6 weeks of thyroxin replacement therapy is usu-
ally needed to correct dyslipidemia in overt hypothyroidism. 
In general, changes in serum lipoproteins in hypothyroid 
patients are correlated with changes in free T4 (FT4) [66]. A 
study in newly-diagnosed hypothyroid patients (n=60) 
showed a decrease in serum TC and LDL-C levels after thy-
roxine treatment [28]. However, when the effects of substitu-
tion therapy on qualitative lipid profile were assessed no 
change in LDL particle size was seen [28]. A more dramatic 
reduction of TC levels has been observed in hypothyroid 
patients with higher baseline TSH levels [67].  
  Serum HDL-C levels tend to decrease with thyroid re-
placement, but this is a less consistent finding [68]. Serum 
Lp(a) levels also tend to decrease with restoration of euthy-
roidism [25, 39]. Moreover, a decrease in CIMT has been 
observed after thyroxine treatment in hypothyroid patients 
[61].  
  The presence of overt hypothyroidism in patients with 
dyslipidemia is not rare. We found that 2.8% of the patients 
who visited our outpatient lipid clinic with dyslipidemia had 
elevated levels of TSH and reduced levels of FT4 [25]. After 
restoration of euthyroidism with levothyroxine therapy, a 
significant decrease of serum levels of TC and LDL-C, apol-
ipoprotein B (ApoB) and Lp(a) was observed, while levels of 
HDL-C, TGs and apolipoprotein AI (ApoAI) were not sig-
nificantly changed [25]. Superimposed dyslipidemia should 
be taken into account in cases of failure of substitution ther-
apy to normalize the lipid profile despite the restoration of 
euthyroidism [1].  
  Hypothyroidism is one of the most common causes of 
secondary dyslipidemia. Therefore, before starting hypolipi-
demic therapy, the evaluation of thyroid function is needed. 
Thyroid failure is associated with increased levels of creatin-
ine kinase (CK) [69]. Statin therapy may substantially in-
crease levels of CK. A study examined the effects of acci-
dentally starting statin therapy in patients with undiagnosed 
hypothyroidism (n=9) [70]. These patients had significantly 
higher CK levels (1095 U/L) compared with untreated hypo-
thyroid patients matched for freeT4 levels (n=18; CK=395; 
p<0.05) [70]. Therefore, it is imperative to firstly correct 
thyroid dysfunction with thyroxine substitution therapy and 
then treat the underlying dyslipidemia with statins. 
ii. Subclinical Hypothyroidism 
  Subclinical hypothyroidism (SH), defined as the clinical 
status of elevated serum TSH levels with normal levels of 
FT4 and FT3, is a far more common disorder than overt hy-
pothyroidism. The prevalence of SH in the general popula-
tion is estimated at 4.3% - 9% [3, 71]. SH has a higher 
prevalence among women and older populations [3, 72-74]. 
Moreover, SH may progress to overt hypothyroidism. The 
rate of progression is higher with the concomitant presence 
of thyroperoxidase antibodies (TPO-Ab) or higher levels of 
TSH [75]. 
a. Lipid Profile 
  SH is associated with increased levels of TC and LDL-C 
[63, 72, 74, 76-80]. In addition, some studies have shown 
that SH dyslipidemia may also be accompanied by increased 
TGs [81, 82] and decreased HDL-C levels [83]. Moreover, 
subjects with high normal TSH levels (2-4 mIU/L), but with 
positive antithyroid antibodies may also exhibit elevated 
cholesterol levels [84]. In a cross-sectional study we evalu-
ated serum lipid parameters of SH patients (n=66) and age- 
and sex- matched euthyroid controls (n=75) [85]. Patients 
with SH had significantly higher levels of TC, LDL-C and 
ApoB, whereas levels of TGs, HDL-C and ApoAI did not 
differ significantly compared with euthyroid controls [85]. 
Similarly, results from the fifth Tromso Study showed in-
creased levels of LDL-C in SH patients (n=84) [86]. 
  Most studies have shown increased Lp(a) levels related 
to SH [85, 87, 88]. An interesting study evaluated serum 
Lp(a) levels along with corresponding apolipoprotein(a) 
[apo(a)] phenotypes, which are known to influence Lp(a) 
levels, in SH patients [89]. SH patients had higher Lp(a) lev-
els compared with controls (p=0.003). Of note, no significant 
difference in the frequencies of apo(a) phenotypes were de-
tected between patients with SH (n=69) and controls (n=83). 
  Thyroid autoimmunity may also play an important role in 
the elevation of Lp(a) levels. It has been reported that euthy-
roid males and postmenopausal females with evidence of 
thyroid autoimmunity (increased titers of TPO-Ab and/or 
thyroglobulin autoantibodies) have increased Lp(a) levels 
[90]. On the other hand, a study compared the levels of Lp(a) 
of 22 euthyroid subjects (9 male and 13 postmenopausal 
female) with thyroid autoimmunity with those of 64 age- and 
sex-matched controls without thyroid autoimmunity [91]. 
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parameters, including Lp(a), between the two groups even 
when apo(a) phenotypes were taken into account [91]. 
Moreover, no significant difference in the Lp(a) levels was 
found in euthyroid patients with chronic renal failure regard-
less of the presence of thyroid autoimmunity, the apo(a) 
phenotype, the stage of renal failure and the mode of dialysis 
in end stage patients [92]. Furthermore, the presence of thy-
roid autoimmunity has not been shown to influence serum 
lipid parameters in SH subjects [85]. 
  There is some controversy regarding the presence or the 
severity of SH-induced dyslipidemia. Indeed, there have 
been studies indicating no significant difference in lipid pro-
file between SH patients and controls [29-31, 93]. Data from 
the NHANES III revealed increased levels of TC in SH pa-
tients (n=215) vs controls (n=8013) [94]. However, when 
adjusted for age, race, sex and the use of lipid-lowering 
drugs no difference was observed between SH and controls 
regarding lipid profile. Moreover, there have been studies 
questioning the effects of thyroid hormones on Lp(a) levels. 
Various studies have shown no difference between SH and 
control subjects regarding Lp(a) levels [39, 82, 95, 96]. Lee 
et. al compared patients covering the whole spectrum of thy-
roid function and found no differences in Lp(a) between 
groups [31]. Moreover, no correlation was found between 
Lp(a) levels and TSH or FT4 [31]. On the contrary, in a study 
with SH patients (n=38) a significant negative correlation 
(r=-0.31; p=0.03) was observed between FT3 levels and 
Lp(a) [82]. 
  An association between lipids, thyroid function and insu-
lin resistance has been observed [18]. The analysis of a sub-
group from the Fremantle Diabetes Study (FDS) showed that 
the association of TSH levels and lipid profile is significant 
mainly in the presence of insulin resistance. Similar results 
were shown in a study in euthyroid subjects [97]. 
  An interesting aspect of the potential SH-mediated 
dyslipidemia is the qualitative effects of thyroid hormones 
on lipids. A study compared SH women (n=21) with female 
controls (n=11) [93]. No difference was found regarding 
lipid profile between the 2 groups. However, decreased ratio 
of cholesterol/triglycerides in LDL (p<0.02) in SH subjects 
vs controls indicated the presence of more TG-enriched LDL 
particles in those subjects. On the other hand, a study in SH 
patients (n=57) did not reveal any differences in LDL parti-
cle size compared with controls [42]. 
b. CVD Risk 
  Beyond lipids, SH can have a deleterious effect on sev-
eral other CVD risk factors. SH has been associated with a 
hypercoagulable state [77, 83]. Furthermore, SH impairs 
ventricular function as well as cardiovascular and respiratory 
adaptation to effort and decreases heart rate variability [98, 
99]. Moreover, SH decreases flow-mediated vasodilation   
and nitric oxide (NO) availability, which are markers of   
endothelial function [98, 99]. An increase in CIMT has also 
been described in SH patients compared with controls [78, 
79]. However, a study in SH patients (n=21) did not confirm 
such an increase in CIMT compared with euthyroid subjects 
[100]. Although SH patients with TPO-Ab had higher CIMT 
values compared with SH patients without TPO-Ab this   
difference was not significant [100]. 
  A study showed a higher incidence of multi-vessel dis-
ease in angina patients (n=344) with high TSH values al-
though TSH was not established as a predictor for coronary 
artery stenosis [101]. On the other hand, a study in hypothy-
roid patients (n=794, 90% of whom had SH) did not reveal 
any differences regarding carotid atherosclerosis (carotid 
plaques prevalence, severity and CIMT) compared with 
euthyroid subjects (n=1588) after adjusting for various CVD 
risk factors [102]. SH has also been associated with other 
CVD risk factors, such as increase in insulin resistance [64, 
103]. 
  SH subjects have been described to have higher plasma 
lipoprotein-associated phospholipase A2 (Lp-PLA2) (which 
is a known CVD marker [104]) and lower HDL Lp-PLA2 
(which is associated with the antiatherogenic effects of HDL 
[105]) activity [81]. Moreover, a negative association be-
tween free thyroxine and hsCRP levels has been described 
[106]. Indeed, increased hsCRP levels have been found in 
SH patients [49]. A study demonstrated a linear correlation 
between blood pressure and TSH even within the normal 
reference ranges [107]. However, a large cross-sectional 
study in SH patients (n=806) did not find any association 
between SH and increased blood pressure [108]. In addition, 
smoking may deteriorate the lipid profile in women with SH 
and aggravate the degree of thyroid failure, thus contributing 
to the development of atherosclerosis [109]. 
  As described above, SH is positively correlated with in-
creased prevalence of some CVD risk factors. However, it is 
imperative to investigate the available data on the incidence 
of CVD morbidity and mortality in SH subjects. A meta-
analysis of 14 trials found an increase in risk of CVD (odds 
ratio [OR] 1.65; 95% CI 1.28-2.12) in subjects with SH 
[110]. An interesting study evaluated the association of SH 
with the incidence of congestive heart failure (CHF), CAD, 
stroke, peripheral artery disease and CVD or total mortality 
[111]. This was a prospective analysis in a longitudinal co-
hort study of older adults (aged 70-79 years old) from the 
Health, Aging, and Body Composition (HEALTH ABC) 
study. SH subjects (n=338) were subdivided in groups ac-
cording to their TSH levels. Patients with TSH levels 7 
mIU/L had a greater risk for CHF (p=0.006). SH was not 
associated with increased prevalence of stroke, peripheral 
artery disease and CVD mortality. However, SH subjects 
with TSH 10 mIU/L had a higher risk for myocardial in-
farction (MI) (hazard ratio [HR] 4.73 95% CI 1.01-22.13) 
and total mortality (HR 3.13 95% CI 1.11-8.79). Similarly, a 
recent meta-analysis found a 41% increase in all cause mor-
tality in SH patients compared with euthyroid subjects [112]. 
Another study in SH patients (n=257) found a positive corre-
lation between SH, CAD and total mortality which however 
was limited only to men (OR 4; 95% CI 1.4 - 11.5) [113].  
  Of interest are the results from studies evaluating the 
effects of SH in elderly populations. The Rotterdam study 
found an association between SH and aortic atherosclerosis 
(OR 1.7; 95% CI 1.1 - 2.6) and MI (OR 2.3; 95% CI 1.3 - 4) in 
elderly SH women [114]. Moreover, the presence of TPO-
Ab increased the risk for both aortic atherosclerosis (OR 1.9; 
95% CI 1.1 - 3.6) and MI (OR 3.1; 95% CI 1.5 - 6.3). However, 
the presence of TPO-Ab in total study population was not 
associated with a history of MI. On the other hand, the Car-
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tween SH and CVD morbidity and mortality in an elderly SH 
population, although an increased incidence of atrial fibrilla-
tion was observed [115]. Moreover, a study evaluated the 
association of thyrotropin with disability and survival in the 
Leiden 85-Plus Study elderly population [116]. The results 
indicated that abnormally high levels of thyrotropin not only 
did not affect cognitive and mental status but rather pro-
longed life span [116]. 
c. Substitution Therapy 
  A beneficial effect of substitution therapy on lipid pa-
rameters and especially TC and LDL-C in some patients 
with SH has been shown [30, 72, 88, 117-120]. In a meta-
analysis, the mean decrease of serum TC and LDL-C levels 
after thyroxine substitution was -7.9 mg/dL and -10 mg/dL, 
respectively [72]. The reduction was larger in individuals 
with higher pretreatment cholesterol levels and in hypothy-
roid individuals taking suboptimal T4 doses [72]. The fifth 
Tromso study [86] evaluated the effects of thyroxine (n=32) 
compared with placebo (n=32) in SH patients. Thyroxine 
was administered with a goal of TSH levels of 0.5-1.5 
mIU/L. The effect of thyroxine therapy on lipid profile was a 
significant decrease of only ApoB levels (p<0.01). However, 
when examining the subgroup of patients (n=23) with post-
treatment TSH levels 0.2-2 mIU/L a significant decrease in 
TC (p<0.05) and LDL-C (p<0.01) was also seen. Moreover, 
thyroxine substitution therapy may have additional advanta-
geous effects to offer beyond the improvement of lipid pro-
file. Indeed, a reduction in CIMT [78, 79] and improvement 
of endothelial function [99] has been described in SH pa-
tients after thyroxine replacement. In addition, thyroxine 
therapy increased HDL-associated Lp-PLA2 activity in SH 
subjects [81]. 
  These findings, however, are not consistently corrobo-
rated by other studies. Indeed, some studies showed no sig-
nificant effect of thyroxine therapy on lipid profile in SH 
patients [78, 93, 121, 122]. Interesting were the results of a 
study evaluating the effects of thyroxine in SH subjects 
(n=66) [85]. Lipid profile was not significantly altered with 
the exception of a decrease in HDL-C levels (p<0.05). How-
ever, in the subgroup of patients with TC 240 mg/dL 
(n=14) or TSH 10 mIU/L (n=18) a decrease in TC (p<0.05) 
and LDL-C (p<0.01) was also observed. A recent meta-
analysis showed no benefits in survival or CVD mortality 
after substitution therapy in SH patients [123]. Moreover, 
thyroxine replacement did not improve quality of life, al-
though a beneficial effect was seen in some lipid parameters 
and left ventricular function [123]. 
  The beneficial effects of thyroxine substitution therapy 
on Lp(a) levels in SH subjects are also debated. Several stud-
ies have shown no impact of thyroxine therapy on Lp(a) lev-
els in SH patients [39, 40, 85, 88]. However, other studies 
showed a significant decrease of Lp(a) levels after thyroxine 
treatment [89, 118]. A study with 17 SH women demon-
strated a reduction of Lp(a) by 23.5% (p=0.0005) compared 
with baseline after substitution therapy [118]. Milionis et al. 
demonstrated that thyroxine treatment was effective in re-
ducing Lp(a) levels in SH subjects (p=0.008) [89]. Of inter-
est was that this reduction of Lp(a) levels achieved signifi-
cance only in the low molecular weight apo(a) isoforms sub-
group of patients [89]. 
d. Should we Treat SH Patients? 
  Although it is clear that thyroid replacement therapy has 
beneficial effects on serum lipid profile and CVD risk in 
overt hypothyroid patients, no clear consensus has been es-
tablished regarding the treatment of SH subjects [124, 125]. 
This is due to the fact that there are no data from large trials 
on whether and to what degree does SH affect lipid profile. 
Moreover, data are lacking on the overall effect of substitu-
tion therapy on morbidity and mortality in SH patients. A 
significant query is whether all SH patients would benefit 
from thyroxine replacement therapy or such therapy should 
be reserved for selected subgroups. Furthermore, there has 
not been enough evidence regarding the long-term effects of 
thyroid replacement in SH patients and therefore no clear 
recommendations can be made [126]. 
  It seems that thyroid substitution, if used, would be most 
beneficial in patients with prominent thyroid dysfunction 
(TSH levels >10 mIU/L), higher initial cholesterol levels, 
smokers and subjects with positive TPO-Ab. Moreover, 
levothyroxine treatment may play an important role in other 
aspects of CVD risk beyond lipids. Of note, the potential 
adverse effects of levothyroxine therapy should also be taken 
into account. Thyroid substitution may decrease HDL-C 
concentration, undermining the beneficial effect of TC and 
LDL-C reduction in these patients. Furthermore, when treat-
ing people with angina pectoris or heart disease, one should 
be very cautious because thyroxin therapy may exacerbate 
angina or promote cardiac arrhythmia. 
  Overall, measurement of serum TSH levels should be 
included in the screening of patients with dyslipidemia [1, 
127, 128]. Hypercholesterolemic patients with SH may be 
treated with thyroxin substitution therapy, since the restora-
tion of euthyroidism can effectively improve lipid levels, 
relieve certain symptoms, and may also prevent progression 
to overt hypothyroidism [129]. 
4. OVERT AND SUBCLINICAL HYPERTHYROIDISM 
  The incidence of hyperthyroidism is lower (2.2%) [3] 
compared with hypothyroidism in the general population. 
Similarly, a decreased prevalence of hyperthyroidism is evi-
dent in hyperlipidemic patients, since only 3 out of the 248 
patients in our study had thyrotoxicosis [25]. 
  Despite the increased activity of the HMG-CoA reduc-
tase, levels of TC, LDL-C, ApoB and Lp(a) tend to decrease 
in patients with clinical or subclinical hyperthyroidism. This 
is due to increased LDL receptor gene expression resulting 
in enhanced LDL receptor-mediated catabolism of LDL par-
ticles [130, 131]. Moreover, no difference in LDL subfrac-
tion distribution has been observed between subclinical or 
overt hyperthyroid versus euthyroid subjects [42]. Further-
more, hyperthyroidism results in enhanced LDL oxidability, 
which is related to FT4 levels [46]. 
  A decrease in HDL-C levels is also observed in hyperthy-
roidism, due to increased CETP-mediated transfer of choles-
teryl esters from HDL to VLDL and increased HL-mediated 
catabolism of HDL2 [130, 131]. Triglyceride levels remain 
unchanged. On the other hand, no changes in blood pressure 
[108], Lp(a) [31] or hsCRP levels [31] have been described 
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activity has been observed in subclinical hyperthyroidism 
patients, indicating a hypercoagulable state [77]. Therapy of 
clinical hyperthyroidism results in restoration of those altera-
tions of lipid metabolism [130, 131], while the effects of 
treatment of subclinical hyperthyroidism subjects are not yet 
clear [132]. 
  Iatrogenic hyperthyroidism has been associated with MI 
in subjects without coronary stenosis [133, 134]. Similarly, 
there have been case reports associating subclinical hyper-
thyroidism with MI [135], recurrent pulmonary embolism 
[136] and atrial fibrillation [135, 136]. 
  Hyperthyroidism not only consists a significant cause of 
acquired hypobetalipoproteinemia, but it can also be the un-
derlying cause of unexpected improvement of lipid profile in 
hyperlipidemic patients [137]. In the latter case, therapy of 
thyrotoxicosis restores the lipid parameters to the previously 
elevated levels [137]. 
5. CONCLUSION 
  Thyroid dysfunction can have an important effect on 
lipid profile [138]. Biochemical screening for thyroid dys-
function is critical in all dyslipidemic patients, as well as in 
all patients with unexpected improvement or worsening of 
their lipid profile. Underlying thyroid disorders should be 
recognized and treated in this setting.  
  There have been studies suggesting that screening for 
thyroid dysfunction is cost effective [139]. The American 
Thyroid Association recommends that adults be screened for 
thyroid dysfunction by measurement of the serum TSH con-
centration, beginning at age 35 years and every 5 years 
thereafter [140]. On the other hand, the U.S. Preventive 
Services Task Force concludes that the evidence is insuffi-
cient to recommend for or against routine screening for thy-
roid disease in adults [141].  
  There is a need for large studies designed to answer the 
question whether thyroid abnormalities (and especially SH) 
are associated with CVD and whether restoration of euthy-
roidism might influence morbidity and mortality. 
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